nct_id: NCT03547973
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2018-06-06'
study_start_date: '2018-08-13'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Cisplatin'
  - drug_name: 'Drug: Enfortumab Vedotin'
  - drug_name: 'Drug: Domvanalimab'
  - drug_name: 'Drug: Carboplatin'
  - drug_name: 'Drug: Avelumab'
  - drug_name: 'Drug: Sacituzumab Govitecan-hziy'
  - drug_name: 'Drug: Gemcitabine'
  - drug_name: 'Drug: Zimberelimab'
  - drug_name: 'Drug: Pembrolizumab'
long_title: A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally
  Advanced/Metastatic Urothelial Cancer
last_updated: '2025-04-15'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: Gilead Sciences
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 827
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Key Inclusion Criteria:'
- 'Inclusion Criteria for All Cohorts:'
- "* Female or male individuals, \u2265 18 years of age (19 Years old for South Korea)."
- '* Eastern Cooperative Oncology Group (ECOG) Performance status score of 0 or 1.'
- '* Adequate renal and hepatic function.'
- '* Adequate hematologic parameters without transfusional support.'
- '* Individuals must have a 3-month life expectancy.'
- 'Additional Inclusion Criteria for Cohorts 1 to 6:'
- '* Cohort 1: Have had progression or recurrence of urothelial cancer following receipt
  of platinum-containing regimen (cisplatin or carboplatin):'
- 1. Received a first-line platinum-containing regimen in the metastatic setting or
  for inoperable locally advanced disease;
- "2. Or received neo/adjuvant platinum-containing therapy for localized muscle-invasive\
  \ urothelial cancer, with recurrence/progression \u226412 months following completion\
  \ of therapy."
- '* Cohort 1: In addition to above criterion, have had progression or recurrence
  of urothelial cancer following receipt of an Anti-programmed Cell Death Protein
  1 (anti-PD-1)/ Anti-programmed Death Ligand 1 (PD-L1) therapy.'
- '* Cohort 2: Were ineligible for platinum-based therapy for first line metastatic
  disease and have had progression or recurrence of urothelial cancer after a first-line
  therapy for metastatic disease with anti-PD-1/PD-L1 therapy. Individual may not
  have received any platinum for treatment of recurrent, metastatic or advanced disease.'
- '* Cohort 3: Progression or recurrence of UC following a platinum containing regimen
  in the metastatic setting, or progression or recurrence of UC within 12 months of
  completion of platinum-based therapy as neoadjuvant or adjuvant therapy.'
- '* Cohort 4: Individual has not received any platinum-based chemotherapy in the
  metastatic or unresectable locally advanced setting. Creatinine clearance of at
  least 50 mL/min calculated by Cockcroft-Gault formula or another validated tool.
  For individuals receiving cisplatin at 70 mg/m\^2 on Day 1 of every 21-day cycle,
  a creatinine clearance of least 60 mL/min calculated by Cockcroft -Gault formula
  or another validated tool is required. Individuals with creatinine clearance between
  50 to 59 mL/min are to receive a split dose of cisplatin (35 mg/m\^2 Day 1 and Day
  8 of every 21-day cycle).'
- '* Cohorts 4, 5, 6: Archival tumor tissue comprising muscle-invasive or metastatic
  urothelial carcinoma, or a biopsy of metastatic urothelial carcinoma.'
- '* Cohort 5: Individuals received at least 4 cycles and no more than 6 cycles of
  GEM + cisplatin. No other chemotherapy regimens are allowed in this cohort, with
  the exception of prior adjuvant or neoadjuvant systemic therapy with curative intent
  after \> 12 months from completion of therapy.'
- '* No evidence of progressive disease following completion of first-line chemotherapy
  (ie, CR, PR, or SD per RECIST v1.1 guidelines as per investigator).'
- '* Treatment-free interval of 4 to 10 weeks since the last dose of chemotherapy.'
- "* Cohort 6: Cis-ineligible and no prior therapy for metastatic disease or for unresectable\
  \ locally advanced disease. Checkpoint inhibitor therapy na\xEFve or \\>12 months\
  \ from completion of adjuvant therapy are permitted."
- '* Cohorts 4 and 6: Have measurable disease by CT or MRI as per RECIST 1.1 criteria.
  Tumor lesions situated in a previously irradiated area are considered measurable
  if progression has been demonstrated in such lesions.'
- "* Cohorts 1, 2, 3 and 5: Creatinine clearance \u2265 30 mL/min as calculated by\
  \ the Cockcroft-Gault formula unless otherwise specified"
- 'Additional Inclusion Criteria for Cohort 7:'
- '* No prior systemic therapy for locally advanced or metastatic UC. Therapy in the
  curative setting is allowed provided recurrence is \> 12 months since the last dose
  of systemic therapy.'
- '* Archival tumor tissue comprising muscle-invasive or metastatic urothelial carcinoma,
  or a biopsy of metastatic urothelial carcinoma.'
- '* Have measurable disease by CT or MRI as per RECIST 1.1 criteria. Tumor lesions
  situated in a previously irradiated area are considered measurable if progression
  has been demonstrated in such lesions.'
- 'Exclude - Key Exclusion Criteria:'
- 'Exclude - Exclusion Criteria for All cohorts:'
- Exclude - * Females who are pregnant or lactating.
- "Exclude - * Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks\
  \ prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline)\
  \ from adverse events due to agents administered more than 4 weeks earlier."
- Exclude - * Has an active second malignancy.
- Exclude - * Has known active Hepatitis B or Hepatitis C.
- Exclude - * Has other concurrent medical or psychiatric conditions.
- Exclude - * Has known active central nervous system (CNS) metastases and/or carcinomatous
  meningitis.
- Exclude - * Has an active second malignancy.
- 'Exclude - Additional Exclusion Criteria for Cohorts 1 to 6:'
- "Exclude - * For Cohort 5: Alopecia, sensory neuropathy Grade \u22642 is acceptable,\
  \ or other Grade \\<\\< 2 adverse events not constituting a safety risk based on\
  \ the investigator's judgment are acceptable."
- 'Exclude - * Cohort 3: Has received anti-PD-1/PD-L1 therapy previously.'
- 'Exclude - * Cohorts 3 to 6: Has an active autoimmune disease that required systemic
  treatment in past 2 years (ie, with use of disease-modifying agents, corticosteroids,
  or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic
  corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not
  considered a form of systemic treatment.'
- 'Exclude - * Cohorts 3 to 6: Has received a live vaccine within 30 days prior to
  the first dose of study drug(s), has history or evidence of interstitial lung disease
  (ILD) or non-infectious pneumonitis.'
- "Exclude - * Cohort 4: Refractory to platinum (i.e., relapsed \u2264 12 months after\
  \ completion of chemotherapy) in the neoadjuvant/adjuvant setting."
- 'Exclude - * Cohorts 4, 5, and 6: For individuals who received prior CPI, a treatment-free
  interval \>12 months between the last treatment administration and the date of recurrence
  is required.'
- 'Exclude - Additional Exclusion Criteria for Cohort 7:'
- Exclude - * Have had a prior anticancer therapy within 12 months prior to C1D1 or
  prior radiation therapy within 2 weeks prior to C1D1. Individuals participating
  in observational studies are eligible. Use of other investigational drugs (drugs
  not marketed for any indication) within 28 days or 5 half-lives (whichever is longer)
  of first dose of investigational product.
- Exclude - * Have a history of idiopathic pulmonary fibrosis, organizing pneumonia,
  drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
  on screening chest CT scan.
- Exclude - * Have a Child-Pugh score of B or C.
- Exclude - * Individuals with uncontrolled diabetes.
- Exclude - * Have active keratitis or corneal ulcerations.
- "Exclude - * Participants with ongoing sensory or motor neuropathy Grade \u2265\
  \ 2."
- 'Exclude - Note: Other protocol defined Inclusion/Exclusion criteria may apply.'
short_title: Study of Sacituzumab Govitecan in Participants With Urothelial Cancer
  That Cannot Be Removed or Has Spread
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Gilead Sciences
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The objective of this study is to evaluate the efficacy and safety of sacituzumab
  govitecan-hziy monotherapy and with novel combinations in participants with metastatic
  urothelial cancer (mUC).
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Cohort 1: Sacituzumab Govitecan-hziy (SG)'
      arm_internal_id: 0
      arm_description: Participants with urothelial cancer (UC) previously treated
        with platinum-based and/or checkpoint inhibitors (CPIs) will receive SG 10
        mg/kg intravenously (IV) on Days 1 and 8 of a 21-day cycle.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 2: SG'
      arm_internal_id: 1
      arm_description: Participants with UC who are ineligible for platinum-based
        therapy and failed therapy with previous immune CPI therapy will receive SG
        10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 3: SG + Pembrolizumab'
      arm_internal_id: 2
      arm_description: Participants who have had progression or recurrence of UC following
        a platinum-containing regimen in the metastatic setting, or progression or
        recurrence of UC within 12 months of completion of platinum-based therapy
        as neoadjuvant or adjuvant therapy will receive SG 10 mg/kg intravenously
        on Days 1 and 8 of a 21-day cycle and pembrolizumab at the standard approved
        dose (200 mg) only on Day 1 of a 21-day cycle. Lower doses of SG may be tested
        based on dose-limiting toxicities (DLTs) observed to determine the Recommended
        Phase 2 Dose (RP2D) of SG in combination with pembrolizumab.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Pembrolizumab'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Cohort 4: SG + Cisplatin + Avelumab (Dose Escalation Phase)'
      arm_internal_id: 3
      arm_description: Participants with UC who have never received therapy with platinum
        in the metastatic setting or for unresectable locally advanced disease will
        first receive cisplatin (either at 70 mg/m\^2 on Day 1 of a 21-day cycle or
        at a split dose of 35 mg/m\^2 on Days 1 and 8 of a 21-day cycle with a maximum
        body surface area of 2) and sacituzumab govitecan-hziy with maximum dose of
        10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle for up to 6 cycles.
        Based on DLTs observed, two additional lower doses may be tested to determine
        RP2D of sacituzumab govitecan-hziy in combination with cisplatin. If premature
        termination of 1 agent occurs due to toxicity, the other agent may be continued
        to complete up to 6 cycles of therapy. For participants who have not progressed,
        maintenance therapy will begin with infusions of avelumab 800 mg every 2 weeks
        beginning on Cycle 1, Day 1 and every 2 weeks thereafter and sacituzumab govitecan-hziy
        10 mg/kg on Days 1 and 8 every 21 days.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Cisplatin'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Avelumab'
        level_internal_id: 2
        level_suspended: N
    - arm_code: 'Cohort 4: SG + Cisplatin + Zimberelimab (ZIM) (Dose Expansion Phase)'
      arm_internal_id: 4
      arm_description: Participants with UC who have never received therapy with platinum
        in the metastatic setting or for unresectable locally advanced disease will
        first receive cisplatin (either at 70 mg/m\^2 on Day 1 of a 21-day cycle or
        at a split dose of 35 mg/m\^2 on Days 1 and 8 of a 21-day cycle with a maximum
        body surface area of 2) and sacituzumab govitecan-hziy with maximum dose of
        10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle for up to 6 cycles.
        If premature termination of 1 agent occurs due to toxicity, the other agent
        may be continued to complete up to 6 cycles of therapy. For participants who
        have not progressed, maintenance therapy will begin with infusions of sacituzumab
        govitecan-hziy 10 mg/kg on Days 1 and 8 every 21 days and zimberelimab 360
        mg every 3 weeks (Day 1 of a 21-day cycle).
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Cisplatin'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Zimberelimab'
        level_internal_id: 2
        level_suspended: N
    - arm_code: 'Cohort 5 (Arm 1): SG + ZIM'
      arm_internal_id: 5
      arm_description: Participants in Cohort 5 will have completed 4 to 6 cycles
        of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry.
        The safety lead-in will be conducted, in 6 to 8 participants (treated with
        SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every
        3 weeks on a 21-day cycle). Upon completion of the safety lead-in, participants
        will receive SG 10 mg/kg IV on Days 1 and 8 of a 21-day cycle followed by
        ZIM 360 mg IV, every 3 weeks (Q3W) (Day 1 of a 21-day cycle) until PD, unacceptable
        toxicity, or loss of clinical benefit. participants who must discontinue 1
        agent may continue the other until PD, unacceptable toxicity, or loss of clinical
        benefit.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Zimberelimab'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Cohort 5 (Arm 2): Avelumab'
      arm_internal_id: 6
      arm_description: Participants in Cohort 5 will have completed 4 to 6 cycles
        of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry.
        The safety lead-in will be conducted, in 6 to 8 participants (treated with
        SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every
        3 weeks on a 21-day cycle). Upon completion of the safety lead-in, participants
        will be randomized to receive avelumab 800 mg IV every 2 weeks (Q2W) until
        PD, unacceptable toxicity, or loss of clinical benefit.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Avelumab'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 5 (Arm 3): ZIM'
      arm_internal_id: 7
      arm_description: 'Participants in Cohort 5 will have completed 4 to 6 cycles
        of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry.
        The safety lead-in will be conducted, in 6 to 8 participants (treated with
        SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every
        3 weeks on a 21-day cycle).


        Upon completion of the safety lead-in, participants will be randomized to
        receive ZIM 360 mg IV Q3W (Day


        1 of a 21-day cycle) until PD, unacceptable toxicity, or loss of clinical
        benefit.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Zimberelimab'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 6 (Arm 1): SG'
      arm_internal_id: 8
      arm_description: Upon completion of the safety lead-in, participants in Cohort
        6 will be randomized and SG will be administered in cisplatin-ineligible participants
        who have never received therapy in the metastatic setting or for unresectable
        locally advanced disease. Treatment may be discontinued at any time, but participants
        will continue to be followed for tumor response until progression is documented,
        and alternate therapy is initiated. If participants discontinue therapy before
        evidence of radiologic progression, imaging should continue until radiologic
        progression is documented, if feasible.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 6 (Arm 2): SG + ZIM'
      arm_internal_id: 9
      arm_description: Upon completion of the safety lead-in, participants in Cohort
        6 will be randomized and SG in combination with ZIM will be administered in
        cisplatin-ineligible participants who have never received therapy in the metastatic
        setting or for unresectable locally advanced disease. The standard approved
        dose of SG will be used in combination with ZIM. Treatment may be discontinued
        at any time, but participants will continue to be followed for tumor response
        until progression is documented or alternate therapy is initiated. If participants
        discontinue therapy before evidence of radiologic progression, imaging should
        continue until radiologic progression is documented, if feasible.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Zimberelimab'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Cohort 6 (Arm 3): SG + ZIM + Domvanalimab (DOM)'
      arm_internal_id: 10
      arm_description: Upon completion of the safety lead-in, participants in Cohort
        6 will be randomized and SG in combination with ZIM and DOM will be administered
        in cisplatin-ineligible participants who have never received therapy in the
        metastatic setting or for unresectable locally advanced disease.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Zimberelimab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Domvanalimab'
        level_internal_id: 2
        level_suspended: N
    - arm_code: 'Cohort 6 (Arm 4): Carboplatin (CARBO) + Gemcitabine (GEM)'
      arm_internal_id: 11
      arm_description: Upon completion of the safety lead-in, participants in Cohort
        6 will be randomized and CARBO in combination with GEM will be administered
        in cisplatin-ineligible participants who have never received therapy in the
        metastatic setting or for unresectable locally advanced disease. Participants
        without disease progression as assessed by the investigator after completion
        of 4 to 6 cycles of therapy may continue with maintenance therapy (avelumab
        800 mg every 2 weeks) until loss of clinical benefit.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Avelumab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Carboplatin'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Gemcitabine'
        level_internal_id: 2
        level_suspended: N
    - arm_code: 'Cohort 7 (Phase 1: Safety Lad-in and Dose Expansion): SG + Enfortumab
        Vedotin (EV) + ZIM'
      arm_internal_id: 12
      arm_description: 'In the safety lead-in phase, participants will receive a starting
        dose level of SG 7.5 mg/kg IV and starting dose level of EV 1.25 mg/kg IV
        will be administered on Days 1 and 8 of each 21-day cycle and ZIM 360 mg IV
        will be administered on Day 1 of each 21-day cycle.


        In dose-expansion, participants will receive SG IV and EV IV at the RP2Ds
        on Days 1 and 8 of each 21-day cycle and ZIM 360 mg IV on Day 1 of each 21-day
        cycle.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Zimberelimab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Enfortumab Vedotin'
        level_internal_id: 2
        level_suspended: N
    - arm_code: 'Cohort 7 (Phase 2: Arm 1): SG + EV + ZIM'
      arm_internal_id: 13
      arm_description: Upon completion of the Cohort 7 dose-expansion phase, participants
        will receive SG IV at the RP2D in combination with EV IV at the RP2D, and
        ZIM 360 mg IV until PD, unacceptable toxicity, or loss of clinical benefit.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Zimberelimab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Enfortumab Vedotin'
        level_internal_id: 2
        level_suspended: N
    - arm_code: 'Cohort 7 (Phase 2: Arm 2): EV + ZIM'
      arm_internal_id: 14
      arm_description: Upon completion of the Cohort 7 dose-expansion phase, participants
        will receive EV 1.25 mg/kg IV and ZIM 360 mg IV.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Zimberelimab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Enfortumab Vedotin'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Cohort 7 (Phase 2: Arm 3): Optional Dose Optimization SG + EV + ZIM'
      arm_internal_id: 15
      arm_description: Upon completion of the Cohort 7 dose-expansion phase, participants
        will receive SG IV at 1 dose level below the RP2D in combination with EV 1.25
        mg/kg IV and ZIM 360 mg IV.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Sacituzumab Govitecan-hziy'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Zimberelimab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Enfortumab Vedotin'
        level_internal_id: 2
        level_suspended: N
    match:
    - and:
      - or:
        - clinical:
            oncotree_primary_diagnosis: Upper Tract Urothelial Carcinoma
        - clinical:
            oncotree_primary_diagnosis: Bladder Urothelial Carcinoma
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Recurrent
          - Metastatic
          - Locally Advanced
          - Unresectable
          - Advanced
